Cost-effectiveness of chemotherapy for advanced and recurrent cervical cancer: a systematic review
IntroductionAdvanced and recurrent cervical cancer often requires palliative chemotherapy and is associated with poor prognosis. Recently, various systemic therapies—including cytotoxic drugs, anti-angiogenic agents, and immune checkpoint inhibitors—have been evaluated for their cost-effectiveness.M...
Saved in:
Main Author: | Katsuaki Inami |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-07-01
|
Series: | Frontiers in Health Services |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/frhs.2025.1616223/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies
by: T. S. Teptsova, et al.
Published: (2018-11-01) -
Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system
by: T. S. Teptsova, et al.
Published: (2021-02-01) -
Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer
by: Kaixuan Wang, et al.
Published: (2025-06-01) -
Cost-effectiveness study of the MitraClip system for mitral regurgitation treatment in inoperable patients
by: E. G. Fedina, et al.
Published: (2021-09-01) -
NEOADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER
by: O. N. Churuksaeva, et al.
Published: (2016-02-01)